Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. You can see the complete list of today’s Zacks #1 Rank stocks here.īaxter has a long-term earnings growth rate of 12.8%.Īmedisys has a long-term earnings growth rate of 16.3%.ĬONMED has a long-term earnings growth rate 14.9%.īreakout Biotech Stocks with Triple-Digit Profit Potential AMED and CONMED Corporation CNMD, each carrying a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Baxter International Inc. For adjusted earnings per share, the same stands at 42 cents, suggesting a decline of 14.3% from the year-ago reported figure.

Adjusted EPS is now projected between 41 cents and 49 cents compared with the previous projection of 26-36 cents.įor 2019, the Zacks Consensus Estimate for revenues is pegged at $92.8 million, indicating an improvement of 14.1% from the year-ago period. Notably, the company expects revenues to range between $92 million and $94 million (up from the previously guided range of $88.5-$91.5 million). Raised outlook for 2019 instills optimism in the stock. Moreover, acquisitions made by the company in the last few years have not only diversified its revenue base but also expanded customer base. Given the company’s strength in the R&D prospects, Surmodics has long-term goals of generating double-digit top-line growth by the end of calendar 2019 and generating EBITDA margins at or above 30% by fiscal 2021. The company is expected to make continued progress throughout the remainder of fiscal 2019. Moreover, it has also been working through the preclinical studies for the data package that will be utilized to determine the readiness for first in-human clinical trial.

The company’s whole product solutions pipeline and sirolimus-based below-the-knee DCB program deserve a mention in this regard. Surmodics’ continued efforts to bolster R&D stature have been a key catalyst. Management anticipates this segment to witness double-digit revenue growth in fiscal 2019. In fact, the company’s fiscal third-quarter revenues of $24.3 million included $2 million contribution from the SurVeil agreement with Abbott. Surmodics’ IVD unit continues to drive the company’s performance as traditionally the segment has been a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.įurther, the company continues to gain from core Medical Devices unit, which witnessed significant contribution from its SurVeil agreement with Abbott.

Srdx qtr date